Kuripenta 40 Tablet contains Pantoprazole 40 mg, a proton pump inhibitor used to reduce gastric acid secretion. It is primarily indicated for the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis, Zollinger-Ellison syndrome, and other conditions involving excessive stomach acid production. Pantoprazole works by selectively inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby suppressing the final step of acid production. This results in decreased gastric acidity, promoting healing of acid-related damage and relief from symptoms such as heartburn, acid regurgitation, and epigastric pain. Kuripenta 40 is typically administered orally, once daily, preferably before meals, with the dosage and duration tailored according to the severity of the condition and clinical response. It is generally well tolerated, with common side effects including headache, diarrhea, nausea, and abdominal discomfort. Caution is advised in patients with liver impairment, and long-term use should be monitored due to potential risks such as vitamin B12 deficiency and increased susceptibility to gastrointestinal infections. Kuripenta 40 should be used under medical supervision, ensuring appropriate diagnosis and management of acid-related disorders.